New core position *for a copy of our disclaimer click here. This is our opinion and should not serve as advice Kiniksa Pharmaceuticals (Nasdaq: KNSA) Buy Zone = $18-21 PT= $30-40 (by or around … [Read more...] about KNSA Report
Swing Trades
GNMK Coverage Update
GenMark Diagnostics (Nasdaq: GNMK) Coverage Update 2/7/21 Outlook: Bullish PT = $20 (0-24 weeks) About GNMKÂ A commercial-stage medical-diagnostic company marketing its proprietary eSensor … [Read more...] about GNMK Coverage Update
BCRX Updates
With BCRX there are a number of positive features that make it an attractive investment at its current valuation (near 5-year lows; on track to have its second commercial asset approved this year), … [Read more...] about BCRX Updates
LJPC Update
Rating: BTFD (buy the effin dip) Since our initial coverage, the LJPC thesis has been unfolding according to plan. For a look back at the initial story, click here. With RSI approaching oversold … [Read more...] about LJPC Update
Why Buy MTNB?
Matinas Biopharma (NYSE: MNTB) Trade Summary Ticker: MTNB (Last: $1.57)Market Cap: $243MAccumulate: $1.50-1.60Price Target: $2.50-3.50Timeframe: 0-12 weeks Trade … [Read more...] about Why Buy MTNB?
MTNB Buy Alert
MTNB buy $1.53-1.60 Institutional investors are loading up following the JPM conference this week.PT= $2.50FYI I (Sultan) sold 1/4 of my position in LJPCLets's get this bread … [Read more...] about MTNB Buy Alert
MS Trade Alert: LJPC & MYOV
1) MYOV entered with a $15.02 average. I really like the fundamentals of this company. It does not feel like a pump and dump. under $15 is a good place to build a position.2) LPJC entered with a $2.49 … [Read more...] about MS Trade Alert: LJPC & MYOV
Why I am Bullish On This Phase 2b Data
Background Achieve Life Sciences (Nasdaq: ACHV) is a specialty pharmaceutical company developing a plant-based alkaloid "Cytisinicline (AKA cytisine)" as a smoking cessation drug. What is … [Read more...] about Why I am Bullish On This Phase 2b Data
PDUFA Watch: Novartis’ Zolgensma (AVXS-101)
Novartis' PDUFA date is May 2019While approval may not have a significant impact on Novartis' price, a patterns suggests there may be money to be made on Ionis' stock The time is drawing nearer to … [Read more...] about PDUFA Watch: Novartis’ Zolgensma (AVXS-101)
My Number 1 Biotech Stock Pick May 2019
The company I am discussing in this article has a strong potential to run 50-100% in the near-term. Fundamentals and technicals have converged at an intriguing time-point giving me a high degree of … [Read more...] about My Number 1 Biotech Stock Pick May 2019
You must be logged in to post a comment.